Contemporary approach to diagnosis and treatment of neuroblastoma

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 57, Issue 1, 2013, Pages 40-52

  Charron, M ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

3 Iodobenzylguanidine; Neuroblastoma, therapeutics; Radionuclide imaging

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 131; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GALLIUM 68; MONOCLONAL ANTIBODY; PENTETREOTIDE IN 111; TETRAXETAN; TOPOTECAN; VINCRISTINE;

BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; BONE SCINTISCANNING; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DOSIMETRY; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG UPTAKE; EVENT FREE SURVIVAL; HUMAN; IN VITRO STUDY; ISOTOPE LABELING; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NEUROBLASTOMA; NEUTROPENIA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; REVIEW; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT RESPONSE; WHOLE BODY SCINTISCANNING;

3-IODOBENZYLGUANIDINE; ANIMALS; BONE AND BONES; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; DIAGNOSTIC IMAGING; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; INFANT; KINETICS; MALE; MEDICAL ONCOLOGY; MICE; NEUROBLASTOMA; OCTREOTIDE; PATIENT SAFETY; RADIOMETRY; RADIONUCLIDE IMAGING; RADIOPHARMACEUTICALS; RECURRENCE; REMISSION INDUCTION; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION;

EID: 84876531409     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11:1466-77. (Pubitemid 23228250)
2. Modak S, Cheung NK. Neuroblastoma: Therapeutic strategies for a clinical enigma. Cancer Treat Rev 2010; 36: 307-317.
3. Goldsby RE, Matthay KK. Neuroblastoma: evolving therapies for a disease with many faces. Paediatr Drugs 2004;6:107-122.
4. Charron M. Imaging in Pediatric Endocrine Disorders. In: Sperling M, editor. Pediatric Endocrinology. Pennsylvania:W.B. Saunders Company 1996;549-576.
5. Gordon I, Peters AM, Gutman A, Morony S, Dicks-Mireaux C, Pritchard J. Skeletal assessment in neuroblastoma-the pitfalls of iodine-123-MIBG scans. J Nucl Med 1990;31:129-134. (Pubitemid 20059210)
6. Pritchard J, Gordon I, Lashford L, Dicks-Mireaux C. Specificity of iodobenzylguanidine scanning in neuroblastoma. Lancet 1988;1:479. (Pubitemid 18067707)
7. Lashford LS, Moyes J, Ott R, Fielding S, Babich J, Mellors S et al. The biodistribution and pharmacokinetics of meta-iodobenzylguanidine in childhood neuroblastoma. Eur J Nucl Med 1988;13:574-7. (Pubitemid 18049263)
8. Lashford LS, Clarke J, Gordon I, Pritchard J, Kemshead JT. A comparative study of the biodistribution of meta-iodobenzylguanidine (mIBG) and the monoclonal antibody UJ13A in patients and animal models. Prog Clin Biol Res 1988;271:643-54.
9. Naranjo A, Parisi MT, Shulkin BL, London WB, Matthay KK, Kreissman SG et al. Comparison of (1)(2)(3)I-metaiodobenzylguanidine (MIBG) and (1)(3)(1)I-MIBG semi-quantitative scores in predicting survival in patients with stage 4 neuroblastomas report from the Children's Oncology Group. Pediatr Blood Cancer 2011;56:1041-5.
10. Messina JA, Cheng SC, Franc BL, Charron M, Shulkin B, To B et al. Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma. Pediatr Blood Cancer 2006;47:865-74. (Pubitemid 44656106)
11. Hickeson MP, Charron M, Maris JM, Brophy P, Kang TI, Zhuang H et al. Biodistribution of post-therapeutic versus diagnostic (13I)I-MIBG scans in children with neuroblastoma. Pediatr Blood Cancer 2004;42:268-74. (Pubitemid 38235078)
12. Accorsi R, Morowitz MJ, Charron M, Maris JM. Pinhole imaging of 131I-metaiodobenzylguanidine (131I-MIBG) in an animal model of neuroblastoma. Pediatr Radiol 2003;33:688-92. (Pubitemid 37220343)
13. Hesslewood SR, Keeling DH. Frequency of adverse reactions to radiopharmaceuticals in Europe. Eur J Nucl Med 1997;24:1179-82. (Pubitemid 27435029)
14. Howman-Giles R, Shaw PJ, Uren RF, Chung DK. Neuroblastoma and other neuroendocrine tumors. Semin Nucl Med 2007;37:286-302. (Pubitemid 46828965)
15. Shapiro B, Copp JE, Sisson JC, Eyre PL, Wallis J, Beierwaltes WH. Iodine-131 metaiodobenzylguanidine for the locating of suspected pheochromocytoma:experience in 400 cases. J Nucl Med 1985;26:576-85. (Pubitemid 16033416)
16. Wiseman GA, Pacak K, O'Dorisio MS, Neumann DR, Waxman AD, Mankoff DA et al. Usefulness of 123I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma:results from a prospective multicenter trial. J Nucl Med 2009;50:1448-54.
17. Vik TA, Pfluger T, Kadota R, Castel V, Tulchinsky M, Farto JC et al. (123)I-mIBG scintigraphy in patients with known or suspected neuroblastoma:Results from a prospective multicenter trial. Pediatr Blood Cancer 2009;52:784-90.
18. Troncone L, Rufini V, Montemaggi P, Danza FM, Lasorella A, Mastrangelo R. The diagnostic and therapeutic utility of radioiodinated metaiodobenzylguanidine (MIBG). 5 years of experience. Eur J Nucl Med 1990;16:325-35. (Pubitemid 20283547)
19. Schmiegelow K, Simes MA, Agertoft L, Berglund G, Storm-Mathisen I, Andreassen M et al. Radio-iodobenzylguanidine scintigraphy of neuroblastoma:conflicting results, when compared with standard investigations. Med Pediatr Oncol 1989;17:127-30.
20. Jacobson AF, Deng H, Lombard J, Lessig HJ, Black RR. 123I-meta- iodobenzylguanidine scintigraphy for the detection of neuroblastoma and pheochromocytoma:results of a meta-analysis. J Clin Endocrinol Metab 2010;95:2596-606.
21. Hahn K, Charron M, Shulkin BL. Role of MR imaging and iodine 123 MIBG scintigraphy in staging of pediatric neuroblastoma. Radiology 2003;227:908; author reply 908-9.
22. Matthay KK, Shulkin B, Ladenstein R, Michon J, Giammarile F, Lewington V et al. Criteria for evaluation of disease extent by (123)I- metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force. Br J Cancer 2010;102:1319-26.
23. Suc A, Lumbroso J, Rubie H, Hattchouel JM, Boneu A, Rodary C et al. Metastatic neuroblastoma in children older than one year:prognostic significance of the initial metaiodobenzylguanidine scan and proposal for a scoring system. Cancer 1996;77:805-11. (Pubitemid 26055409)
24. Matthay KK, Edeline V, Lumbroso J, Tanguy ML, Asselain B, Zucker JM et al. Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma. J Clin Oncol 2003;21:2486-91. (Pubitemid 46606329)
25. Pashankar FD, O'Dorisio MS, Menda Y. MIBG and somatostatin receptor analogs in children:current concepts on diagnostic and therapeutic use. J Nucl Med 2005;46 Suppl 1:55S-61S. (Pubitemid 47619019)
26. Giammarile F, Chiti A, Lassmann M, Brans B, Flux G, Eanm. EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy. Eur J Nucl Med Mol Imaging 2008;35:1039-47.
27. Olivier P, Colarinha P, Fettich J, Fischer S, Frokier J, Giammarile F et al. Guidelines for radioiodinated MIBG scintigraphy in children. Eur J Nucl Med Mol Imaging 2003;30:B45-50.
28. Bombardieri E, Seregni E, Villano C, Chiti A, Bajetta E. Position of nuclear medicine techniques in the diagnostic work-up of neuroendocrine tumors. Q J Nucl Med Mol Imaging 2004;48:150-63. (Pubitemid 39248302)
29. Taggart D, Dubois S, Matthay KK. Radiolabeled metaiodobenzylguanidine for imaging and therapy of neuroblastoma. Q J Nucl Med Mol Imaging 2008;52:403-18.
30. Bombardieri E, Giammarile F, Aktolun C, Baum RP, Bischof Delaloye A, Maffioli L et al. 131I/123I-metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 2010;37:2436-46.
31. Buckley SE, Chittenden SJ, Saran FH, Meller ST, Flux GD. Whole-body dosimetry for individualized treatment planning of 131I-MIBG radionuclide therapy for neuroblastoma. J Nucl Med 2009;50:1518-24.
32. Lessig MK. The role of 131I-MIBG in high-risk neuroblastoma treatment. J Pediatr Oncol Nurs 2009;26:208-16.
33. DuBois SG, Matthay KK. Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma. Nucl Med Biol 2008;35(Suppl 1):S35-48.
34. Shapiro B, Gross MD. Radiochemistry, biochemistry, and kinetics of 131I-metaiodobenzylguanidine (MIBG) and 123I-MIBG:clinical implications of the use of 123I-MIBG. Med Pediatr Oncol 1987;15:170-7. (Pubitemid 18025972)
35. Shapiro B, Sisson JC, Eyre P, Copp JE, Dmuchowski C, Beierwaltes WH. 131I-MIBG - a new agent in diagnosis and treatment of pheochromocytoma. Cardiology 1985;72(Suppl 1):137-42. (Pubitemid 16146030)
36. Wafelman AR, Hoefnagel CA, Beijnen JH. Radiochemical stability during infusion of 131I-labelled metaiodobenzylguanidine for therapeutic use. Nucl Med Commun 1993;14:819-22. (Pubitemid 23279871)
37. Fielding SL, Flower MA, Ackery D, Kemshead JT, Lashford LS, Lewis I. Dosimetry of iodine 131 metaiodobenzylguanidine for treatment of resistant neuroblastoma:results of a UK study. Eur J Nucl Med 1991;18:308-16.
38. Matthay KK, Panina C, Huberty J, Price D, Glidden DV, Tang HR et al. Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG. J Nucl Med 2001;42:1713-21. (Pubitemid 33131334)
39. Flower MA, Fielding SL. Radiation dosimetry for 131I-mIBG therapy of neuroblastoma. Phys Med Biol 1996;41:1933-40. (Pubitemid 26333632)
40. Buckley SE, Saran FH, Gaze MN, Chittenden S, Partridge M, Lancaster D et al. Dosimetry for fractionated (131)I-mIBG therapies in patients with primary resistant high-risk neuroblastoma:preliminary results. Cancer Biother Radiopharm 2007;22:105-112. (Pubitemid 46697371)
41. Matthay KK, DeSantes K, Hasegawa B, Huberty J, Hattner RS, Ablin A et al. Phase I dose escalation of 131I-metaiodobenzyl-guanidine with autologous bone marrow support in refractory neuroblastoma. J Clin Oncol 1998;16:229-36. (Pubitemid 28041603)
42. DuBois SG, Messina J, Maris JM, Huberty J, Glidden DV, Veatch J et al. Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma. J Clin Oncol 2004;22:2452-60. (Pubitemid 41115404)
43. Howard JP, Maris JM, Kersun LS, Huberty JP, Cheng SC, Hawkins RA et al. Tumor response and toxicity with multiple infusions of high dose 131I-MIBG for refractory neuroblastoma. Pediatr Blood Cancer 2005;44:232-9. (Pubitemid 40209432)
44. Matthay KK, Yanik G, Messina J, Quach A, Huberty J, Cheng SC et al. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol 2007;25:1054-60. (Pubitemid 46596756)
45. Matthay KK, Quach A, Huberty J, Franc BL, Hawkins RA, Jackson H et al. Iodine-131-metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma:a new approaches to neuroblastoma therapy phase I study. J Clin Oncol 2009;27:1020-5.
46. Corbett R, Pinkerton R, Tait D, Meller S. [131I]metaiodobenzylguanidine and high-dose chemotherapy with bone marrow rescue in advanced neuroblastoma. J Nucl Biol Med 1991;35:228-31.
47. Mastrangelo R, Lasorella A, Troncone L, Rufini V, Iavarone A, Riccardi R. [131I]metaiodobenzylguanidine in neuroblastoma patients at diagnosis. J Nucl Biol Med 1991;35:252-254.
48. Mastrangelo R, Tornesello A, Riccardi R, Lasorella A, Mastrangelo S, Mancini A et al. A new approach in the treatment of stage IV neuroblastoma using a combination of [131I]meta-iodobenzylguanidine (MIBG) and cisplatin. Eur J Cancer 1995;31A:606-611.
49. Mastrangelo S, Tornesello A, Diociaiuti L, Pession A, Prete A, Rufini V et al. Treatment of advanced neuroblastoma:feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy. Br J Cancer 2001;84:460-4. (Pubitemid 32215869)
50. Gaze MN, Wheldon TE, O'Donoghue JA, Hilditch TE, McNee SG, Simpson E et al. Multi-modality megatherapy with [131I]meta-iodobenzylguanidine, high dose melphalan and total body irradiation with bone marrow rescue:feasibility study of a new strategy for advanced neuroblastoma. Eur J Cancer 1995;31A:252-6.
51. Klingebiel T, Bader P, Bares R, Beck J, Hero B, Jurgens H et al. Treatment of neuroblastoma stage 4 with 131I-meta-iodobenzylguanidine, high-dose chemotherapy and immunotherapy. A pilot study. Eur J Cancer 1998;34:1398-402. (Pubitemid 28370932)
52. Miano M, Garaventa A, Pizzitola MR, Piccolo MS, Dallorso S, Villavecchia GP et al. Megatherapy combining I(131) metaiodobenzylguanidine and high-dose chemotherapy with haematopoietic progenitor cell rescue for neuroblastoma. Bone Marrow Transplant 2001;27:571-4. (Pubitemid 32401452)
53. Matthay KK, Tan JC, Villablanca JG, Yanik GA, Veatch J, Franc B et al. Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastomas new approaches to Neuroblastoma Therapy Consortium Study. J Clin Oncol 2006;24:500-6. (Pubitemid 46630470)
54. Voute PA, Hoefnagel CA, de Kraker J. 131I-meta-iodobenzylguanidine in diagnosis and treatment of neuroblastoma. Bull Cancer 1988;75:107-11.
55. Garaventa A, Bellagamba O, Lo Piccolo MS, Milanaccio C, Lanino E, Bertolazzi L et al. 131I-metaiodobenzylguanidine (131I-MIBG) therapy for residual neuroblastomas mono-institutional experience with 43 patients. Br J Cancer 1999;81:1378-84.
56. Kang TI, Brophy P, Hickeson M, Heyman S, Evans AE, Charron M et al. Targeted radiotherapy with submyeloablative doses of 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma. J Pediatr Hematol Oncol 2003;25:769-73. (Pubitemid 37238765)
57. Matthay KK, Weiss B, Villablanca JG, Maris JM, Yanik GA, Dubois SG et al. Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma:new approaches to neuroblastoma therapy consortium trial. J Nucl Med 2012;53:1155-63.
58. DuBois SG, Chesler L, Groshen S, Hawkins R, Goodarzian F, Shimada H et al. Phase I study of vincristine, irinotecan, and (1)(3)(1)I- metaiodobenzylguanidine for patients with relapsed or refractory neuroblastomas new approaches to neuroblastoma therapy trial. Clin Cancer Res 2012;18:2679-86.
59. Polishchuk AL, Dubois SG, Haas-Kogan D, Hawkins R, Matthay KK. Response, survival, and toxicity after iodine-131-metaiodobenzylguanidine therapy for neuroblastoma in preadolescents, adolescents, and adults. Cancer 2011;117:4286-93.
60. Mastrangelo S, Rufini V, Ruggiero A, Di Giannatale A, Riccardi R. Treatment of advanced neuroblastoma in children over 1 year of age:the critical role of (1)(3)(1)I-metaiodobenzylguanidine combined with chemotherapy in a rapid induction regimen. Pediatr Blood Cancer 2011;56:1032-40.
61. de Kraker J, Hoefnagel KA, Verschuur AC, van Eck B, van Santen HM, Caron HN. Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age. Eur J Cancer 2008;44:551-6.
62. Picco P, Garaventa A, Claudiani F, Garibaldi L, Borrone C. Primary hypothyroidism and 131I-MIBG therapy in neuroblastoma. Lancet 1993;342:57. (Pubitemid 23183943)
63. Picco P, Garaventa A, Claudiani F, Gattorno M, De Bernardi B, Borrone C. Primary hypothyroidism as a consequence of 131-I-metaiodobenzylguanidine treatment for children with neuroblastoma. Cancer 1995;76:1662-4.
64. Foley TP, Jr., Charron M. Radioiodine treatment of juvenile Graves disease. Exp Clin Endocrinol Diabetes 1997;105 Suppl 4:61-5. (Pubitemid 27523748)
65. Brans B, Monsieurs M, Laureys G, Kaufman JM, Thierens H, Dierckx RA. Thyroidal uptake and radiation dose after repetitive I-131-MIBG treatments:influence of potassium iodide for thyroid blocking. Med Pediatr Oncol 2002;38:41-6. (Pubitemid 34037711)
66. van Santen HM, de Kraker J, van Eck BL, de Vijlder JJ, Vulsma T. High incidence of thyroid dysfunction despite prophylaxis with potassium iodide during (131)I-meta-iodobenzylguanidine treatment in children with neuroblastoma. Cancer 2002;94:2081-9. (Pubitemid 34270064)
67. van Santen HM, de Kraker J, Vulsma T. Endocrine late effects from multi-modality treatment of neuroblastoma. Eur J Cancer 2005;41:1767-74. (Pubitemid 41132640)
68. van Santen HM, de Kraker J, van Eck BL, de Vijlder JJ, Vulsma T. Improved radiation protection of the thyroid gland with thyroxine, methimazole, and potassium iodide during diagnostic and therapeutic use of radiolabeled metaiodobenzylguanidine in children with neuroblastoma. Cancer 2003;98:389-96. (Pubitemid 36828466)
69. Garaventa A, Gambini C, Villavecchia G, Di Cataldo A, Bertolazzi L, Pizzitola MR et al. Second malignancies in children with neuroblastoma after combined treatment with 131I-metaiodobenzylguanidine. Cancer 2003;97:1332-8. (Pubitemid 36237321)
70. Weiss B, Vora A, Huberty J, Hawkins RA, Matthay KK. Secondary myelodysplastic syndrome and leukemia following 131I-metaiodobenzylguanidine therapy for relapsed neuroblastoma. J Pediatr Hematol Oncol 2003;25:543-7. (Pubitemid 36830702)
71. Sisson JC, Yanik GA. Theranostics: evolution of the radiopharmaceutical meta-iodobenzylguanidine in endocrine tumors. Semin Nucl Med 2012;42:171-84.
72. Modak S, Pandit-Taskar N, Kushner BH, Kramer K, Smith-Jones P, Larson S et al. Transient sialoadenitis:a complication of 131I-metaiodobenzylguanidine therapy. Pediatr Blood Cancer 2008;50:1271-3. (Pubitemid 351555558)
73. Kwekkeboom DJ, de Herder WW, van Eijck CH, Kam BL, van Essen M, Teunissen JJ et al. Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 2010;40:78-88.
74. Maecke HR, Reubi JC. Somatostatin receptors as targets for nuclear medicine imaging and radionuclide treatment. J Nucl Med 2011;52:841-4.
75. Kroiss A, Putzer D, Uprimny C, Decristoforo C, Gabriel M, Santner W et al. Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr 3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine. Eur J Nucl Med Mol Imaging 2011;38:865-73.
76. Lauriero F, Rubini G, D'Addabbo F, Rubini D, Schettini F, D'Addabbo A. I-131 MIBG scintigraphy of neuroectodermal tumors. Comparison between I-131 MIBG and In-111 DTPA-octreotide. Clin Nucl Med 1995;20:243-9.
77. Tenenbaum F, Lumbroso J, Schlumberger M, Mure A, Plouin PF, Caillou B et al. Comparison of radiolabeled octreotide and metaiodobenzylguanidine (MIBG) scintigraphy in malignant pheochromocytoma. J Nucl Med 1995;36:1-6.
78. Taal BG, Hoefnagel CA, Valdes Olmos RA, Boot H, Beijnen JH. Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors. J Clin Oncol 1996;14:1829-38. (Pubitemid 26185458)
79. Taal BG, Hoefnagel CA, Valdes Olmos RA, Boot H. Combined diagnostic imaging with 131I-metaiodobenzylguanidine and 111In-pentetreotide in carcinoid tumours. Eur J Cancer 1996;32A:1924-32. (Pubitemid 26361686)
80. Kaltsas G, Korbonits M, Heintz E, Mukherjee JJ, Jenkins PJ, Chew SL et al. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J Clin Endocrinol Metab 2001;86:895-902. (Pubitemid 32207512)
81. Koopmans KP, Jager PL, Kema IP, Kerstens MN, Albers F, Dullaart RP. 111In-octreotide is superior to 123I-metaiodobenzylguanidine for scintigraphic detection of head and neck paragangliomas. J Nucl Med 2008;49:1232-7.
82. Gains JE, Bomanji JB, Fersht NL, Sullivan T, D'Souza D, Sullivan KP et al. 177LU-DOTATATE molecular radiotherapy for childhood neuroblastoma. J Nucl Med 2011;52:1041-7.
83. Menda Y, O'Dorisio MS, Kao S, Khanna G, Michael S, Connolly M et al. Phase I trial of 90Y-DOTATOC therapy in children and young adults with refractory solid tumors that express somatostatin receptors. J Nucl Med 2010;51:1524-31.
84. Kwekkeboom DJ, Bakker WH, Kam BL, Teunissen JJ, Kooij PP, de Herder WW et al. Treatment of patients with gastro-enteropancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate. Eur J Nucl Med Mol Imaging 2003;30:417-22. (Pubitemid 36692868)
85. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008;26:2124-30.